White Paper: Accelerate IL-23 Drug Development with Translational Psoriasis Models
ChemPartner provides integrated translational models designed to evaluate biologics and small molecules targeting the IL-23 pathway.
Our capabilities span biochemical binding assays, pathway-specific cellular systems, primary immune cell models, and validated IL-23– and IMQ–induced psoriasis mouse models, enabling comprehensive evaluation from target engagement through functional efficacy.
This white paper highlights how mechanism-aligned psoriasis models generate decision-ready data that bridge early discovery and clinical development.
Request a Copy of the White Paper to Learn:
- Why IL-23 remains a leading therapeutic target
Explore how the IL-23/IL-17/STAT3 signaling axis drives psoriasis pathology and related autoimmune diseases.
- How to connect target engagement to functional outcomes
Learn how integrated in vitro and in vivo assays – including binding studies, pSTAT3 signaling systems, PBMC models, and cytokine profiling – support translational evaluation.
- How to choose the right psoriasis model
Understand the differences between IL-23–induced and IMQ-induced models and when to use each for biologic or small-molecule development.
- How translational models validate therapeutic mechanisms
See how IL-23 blockade and TYK2 inhibition demonstrate measurable efficacy across key inflammatory endpoints.
Request the White Paper to discover how translational psoriasis models can accelerate IL-23 program evaluation and support more confident candidate selection.
